US 12,213,956 B2
Method of treating fatty acid oxidation disorders using omega3/omega6 unsaturated or branched chain fatty acids
Al-Walid A. Mohsen, Gibsonia, PA (US)
Assigned to University of Pittsburgh—Of the Commonwealth System of Higher Education, Pittsburgh, PA (US)
Filed by University of Pittsburgh—Of the Commonwealth System of Higher Education, Pittsburgh, PA (US)
Filed on Jul. 28, 2021, as Appl. No. 17/387,299.
Application 17/387,299 is a continuation of application No. 17/258,877, granted, now 11,844,775, previously published as PCT/US2019/041321, filed on Jul. 11, 2019.
Claims priority of provisional application 62/696,526, filed on Jul. 11, 2018.
Prior Publication US 2021/0353581 A1, Nov. 18, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/221 (2006.01); A61K 9/00 (2006.01); A61K 31/232 (2006.01); A61P 3/00 (2006.01)
CPC A61K 31/221 (2013.01) [A61K 9/0053 (2013.01); A61K 31/232 (2013.01); A61P 3/00 (2018.01)] 13 Claims
 
1. A method of treating a patient having medium chain acyl-CoA dehydrogenase deficiency (MCADD) comprising administering to a patient an effective amount of an active agent triglyceride comprising one to three fatty acid moieties selected from the group consisting of heptanoyl, 2-methylheptanoyl, 2,6-dimethylheptanoyl, 4,8-dimethylnonanoyl, 6-amino-2,4-dimethylheptanoyl, linolenoyl, docosahexaenoyl, and eicosapentaenoyl in any combination, or a pharmaceutically-acceptable salt thereof, effective to treat the MCADD in a patient.